MBX Biosciences
PublicMBX Biosciences is now publicly traded
The data on this page reflects MBX Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 12, 2024
Last Round
Follow-on Offering
Sep 24, 2025
Total Funding Raised
$603.2M
Company Overview
MBX Biosciences (NAS: MBX) is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative precision peptide therapies aimed at treating endocrine and metabolic disorders.
Sector
Healthcare
AI Layer
Non-AI
Keywords
MBX Biosciences Comparables
Compare MBX Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AstraZeneca | 84% | |
| Roche Holding | 66% | |
| ProLynx Inc. | 39% |
MBX Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Sep 24, 2025 | ||||
| IPO | Sep 12, 2024 | ||||
| Series C | Aug 5, 2024 | ||||
| Series B | Nov 14, 2022 | ||||
| Series A | Jul 27, 2020 | ||||
Seed | Sep 10, 2019 |
MBX Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Follow-on Offering, IPO |
| RA Capital Management | Series C, Series B |
| Frazier Healthcare Partners | Series A |
| Guggenheim Securities | Follow-on Offering, IPO |
| New Enterprise Associates (NEA) | Series C, Series A, Series B |
| BioCrossroads | Seed, Series A |
| Deep Track Capital | Series C |
MBX Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access